// App-Quantinova.ai

BSH2020‐PO‐083 : UK CLL forum 5 years update on 315 relapsed refractory CLL patients treated with ibrutinib in 66 UK and Ireland centres

Researchers

Presenter

  • U. CLL Forum

Principal Investigators

  • N/A

Medical Centers

  • Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Presenilin 2

Drug/Treatment

  • Idelalisib

  • Venetoclax

  • Ibrutinib

  • Rituximab

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved